The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157: Miracle Healing Peptide or Hidden Danger? Multifunctionality and Possible Medical Application of the BPC 157 PeptideLiterature and Patent Review RFK Jr.'s peptide push could unleash risky drugs STAT First Opinion FDA moves toward easing restrictions on certain peptides BioPharma Dive FDA's Overreach on Compounded Peptides